Ann: Engagement of Leading Listing Advisors to NASDAQ IPO, page-33

First 33 Last

Share
Profile

Follow
E5877969

14 Posts.

29

23/04/20

11:36

Post #: 44209213
Share

Originally posted by Galilee13: ↑

Nice work stockfella

Appointing 2 brokers and 1 with an Asian base sets this company up very well, particularly if they still want to IPO the Chinese business on the HKSE.

Timing of Q3 look very ambitious to me. Although things seem to be moving pretty quickly ATM. if they list late Q3 then they may sneak in the Q2 financials. If this is the plan I really hope they bank some serious revenue over the next 2 months. The only other potential deal we know about is with FCL.

They will definitely need FDA for the patch and NMPA for the prizma to get the IPO anyway without any increase in revenue. Hence US and Chinese brokers....

NMPA for the patch and G3 and G4 of the prizma will entice new investors, amongst other things.

But Q3 for CR doesn't help with this Magna CN due next week. I can't see the company doing a CR on ASX for a min of $5m with a Nasdaq raising coming. Maybe they extend the Magna CN for 6mths to coincide. Maybe Yacov just pays it out? Will find out soon enough.

These last few announcements are definitely great, but not price sensitive. They are intentions only. Nothing firm it terms of revenue or raising amounts nor timings.

And yes, if they list on the Nasdaq it WILL dilute the ASX share price. More shares on issue, just tradable across 2
exchanges.

Expand

Hi G13 - To $tockfella's point - what if we go down the HKEx listing route and IPO G Medical USA rather than the parent company proceeding with a dual listing to avoid or minimise dilution? Obviously the details from today's announcement are a little thin but food for thought...

GMV Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 57 more messages in this thread...

First 33 Last

Add GMV (ASX) to my watchlist

Ann: Engagement of Leading Listing Advisors to NASDAQ IPO, page-33

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News